ClinicalTrials.gg
CompletedNCT00038636Updated Aug 15, 2006

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

A Phase 3 interventional study of Lopinavir/ritonavir and Ritonavir in HIV Infections, sponsored by Abbott. Completed at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-08-15.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 124 studies testing ritonavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Ritonavir · HIV Infections.

Enrollment
72nd of 119
36 · median 46
Started
2000
with 4 others
Phase 3
24 of 124
1 open now
Registered
34th of 124
by date
Lead sponsor
6 of 124
Abbott

Among the 124 studies testing ritonavir in HIV Infections, this one is the 72nd largest by enrollment of the 119 interventional ones that give a count, is one of 5 that started in 2000, is one of 24 in phase 3, and was the 34th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 124 studies testing ritonavir in HIV Infections is open now. Recruiting first, the newest first:

About ritonavir

Ritonavir: first FDA approval 1996 (NORVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies testing ritonavir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • positive
  • Are at least 18 years old
  • Subject has not been treated for an active AIDS-defining opportunistic infection within 15 days of screening
  • HIV RNA level > 1000 copies/mL
  • Previous therapy with at least one protease inhibitor, at least one non-nucleoside reverse transcriptase inhibitor and at least one nucleoside reverse transcriptase inhibitor

Exclusion criteria

Exclusion:

  • Subject is pregnant or breast-feeding
  • Subject has received an drug within 30 days prior to screening
  • Have a history of pancreatitis
  • History of intolerance to ritonavir
  • Abnormal laboratory tests at screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Virologic and immunologic activity evaluations include plasma HIV RNA, CD4 and CD8 cell counts

07

Study locations

7 sites
  • UCSD Treatment Center
    San Diego, California 92103-6329, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Hopital Pitie-Salpetriere
    Paris, 75651, France
  • Hospital Europeen Georges Pompidou
    Paris, 75908, France
  • Hospital Clinico de Barcelona
    Barcelona, 08036, Spain
  • Ciutat Sanitaria de Bellvitge
    Barcelona, 08907, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00038636
Lead sponsor
Abbott
First posted
Jun 4, 2002
Start date
Sep 2000
Last update
Aug 15, 2006

Study contacts

Eugene Sun, M.D.
study chair · Divisional Vice President, Infectious Diseases and Virology Dept.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ritonavir

Start the discussion